I am eager to participate in the Hong Kong Laureate Forum 2025 to engage with leading scientists and fellow young researchers. As a dedicated scholar in pharmaceutics, my focus has been on developing aerosol formulations of broad-spectrum antivirals designed to target both the upper and lower respiratory tracts for the prevention and treatment of respiratory viral infections. My research encompasses multidisciplinary projects that align with the Forum’s commitment to fostering interdisciplinary dialogue and innovation. This unique opportunity to interact with esteemed Shaw Laureates and experts will enhance my understanding of current scientific challenges and inspire my future research endeavours. I am particularly excited about participating in workshops and discussions that bridge theoretical knowledge with practical applications. As a Singaporean working in Hong Kong, the Forum's emphasis on cross-cultural exchange resonates deeply with my belief in collaborative science as a means to address global issues. I aim to actively contribute to discussions and share my insights while learning from diverse perspectives. Participating in this Forum will be a pivotal step in my academic journey, equipping me with new ideas and networks to amplify my impact within the scientific community.

My research focuses on developing innovative drug delivery systems targeting respiratory diseases using aerosol technology to achieve optimal deposition in both the upper and lower respiratory tracts. By harnessing both nasal and pulmonary routes, I aim to enhance therapeutic efficacy while minimizing systemic side effects. My PhD work investigates various formulation strategies, including powder and liquid delivery systems, to optimize aerosol performance and ensure effective particle size distribution. The potential for improved patient outcomes has been demonstrated through in vivo animal studies, which highlighted the effectiveness of broad-spectrum antivirals in early treatment scenarios, particularly during viral outbreaks. My current research interest seeks to bridge the gap between laboratory findings and clinical applications, aiming to advance respiratory therapies and establish a robust drug delivery platform. This platform will facilitate the development of novel inhalation products, such as inhaled antivirals and health supplements, ultimately contributing to better management of respiratory conditions.